EMA proposes revision of its overarching biosimilars guideline
This article was originally published in SRA
Executive Summary
The European Medicines Agency is inviting feedback on plans to revise its so-called "overarching" guideline on biosimilars that has been in place since 20051. The proposed revision will take into account current practices companies use to develop these products.